ABSTRACT
The short half-life, favourable nuclear decay properties, convenient availability through [Germanium-68 (Ge-68)/Gallium-68 (Ga-68)] generators, ease of radiolabeling through automated synthesis module and kit methodology and possible combination with Lutetium-177/Yttrium-90 as a theranostic pair for treatment, the radiometal Gallium-68 is increasingly used in diagnostic positron emission tomography. This review discusses the properties of Ge-68/Ga-68 generators, bifunctional chelators that can be efficiently radiolabeled with Ga-68, the way of preparation of Ga-68 radiopharmaceuticals with their quality control.
References
1Nelson BJB, Andersson JD, Wuest F, Spreckelmeyer S. Good practices for 68Ga radiopharmaceutical production. EJNMMI Radiopharm Chem 2022;7:27.
2Velikyan I. 68Ga-Based radiopharmaceuticals: production and application relationship. Molecules 2015;20:12913-12943.
3Lepareur N. Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals? Front Med 2022;9:812050.
4Gleason GI. A positron cow. Int J Appl Radiat Isot 1960;8:90-94.
5Rösch F. Past, present and future of 68Ge/68Ga generators. Appl Radiat Isot 2013;76:24-30.
6Velikyan I. Prospective of 68Ga-Radiopharmaceutical Development. Theranostics 2014;4:47-80.
7Romero E, Martínez A, Oteo M, Ibañez M, Santos M, Morcillo MÁ. Development and long-term evaluation of a new 68Ge/68Ga generator based on nano-SnO2 for PET imaging. Sci Rep 2020;10:12756.
8Zhernosekov KP, Filosofov DV, Baum RP, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48:1741-1748.
9Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 2005;32:478-485.
10Meyer GJ, Mäcke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004;31:1097-1104.
11Waterhouse NN, Amor-Coarasa A, Nikolopoulou A, Babich JW. Otto: a 4.04 GBq (109 mCi) 68Ge/68Ga generator, first of its kind - extended quality control and performance evaluation in the clinical production of [68Ga]Ga-PSMA-11. EJNMMI Radiopharm Chem 2020;5:5.
12Pandey MK, Byrne JF, Jiang H, Packard AB, DeGrado TR. Cyclotron production of (68)Ga via the (68)Zn(p,n)(68)Ga reaction in aqueous solution. Am J Nucl Med Mol Imaging 2014;4:303-310.
13Shetty D, Lee YS, Jeong JM. (68)Ga-labeled radiopharmaceuticals for positron emission tomography. Nucl Med Mol Imaging 2010;44:233-240.
14Parker D. Tumour targeting with radiolabelled macrocycle–antibody conjugates. Chem Soc Rev [Internet]. The Royal Society of Chemistry 1990;19:271-291. Available from: http://dx.doi.org/10.1039/CS9901900271
15Velikyan I. Positron emitting [68Ga]Ga-based imaging agents: chemistry and diversity. Med Chem 2011;7:345-379.
16Jeong JM, Seelam SR, Lee Y-S. Chelators for 68 Ga radiopharmaceuticals. J Radiopharm Mol Probes 2016;2:22-36.
17Satpati D. Recent Breakthrough in 68Ga-Radiopharmaceuticals Cold Kits for Convenient PET Radiopharmacy. Bioconjug Chem 2021;32:430-447.
18De Decker M, Turner JH. Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131. Cancer Biother Radiopharm 2012;27:72-76.
19Meisenheimer M, Saenko Y, Eppard E. Gallium-68: Radiolabeling of Radiopharmaceuticals for PET Imaging - A Lot to Consider. In: Naqvi SAR, Imrani MB, editors. Med Isot. Rijeka: IntechOpen; 2019.
20Kolenc Peitl P, Rangger C, Garnuszek P, et al. Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples. J Labelled Comp Radiopharm 2019;62:673-683.
21Decristoforo C, Neels O, Patt M. Emerging Radionuclides in a Regulatory Framework for Medicinal Products - How Do They Fit? Front Med (Lausanne) 2021;8:678452.
22Decristoforo C. Gallium-68 -- a new opportunity for PET available from a long shelf-life generator - automation and applications. Curr Radiopharm 2012;5:212-220.
23Decristoforo C, Knopp R, von Guggenberg E, et al. A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun 2007;28:870-875.
24Petrik M, Knetsch PA, Knopp R, et al. Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system. Nucl Med Commun 2011;32:887-895.
25Tsionou MI, Knapp CE, Foley CA, et al. Comparison of macrocyclic and acyclic chelators for gallium-68 radiolabelling. RSC Adv 2017;7:49586-49599.
26Young JD, Abbate V, Imberti C, et al. 68Ga-THP-PSMA: A PET Imaging Agent for Prostate Cancer Offering Rapid, Room-Temperature, 1-Step Kit-Based Radiolabeling. J Nucl Med 2017;58:1270-1277.
27Kleynhans J, Rubow S, le Roux J, Marjanovic-Painter B, Zeevaart JR, Ebenhan T. Production of [68 Ga]Ga-PSMA: Comparing a manual kit-based method with a module-based automated synthesis approach. J Labelled Comp Radiopharm 2020;63:553-563.
28Chastel A, Vimont D, Claverol S, et al. 68Ga-Radiolabeling and Pharmacological Characterization of a Kit-Based Formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) Antagonist RM2 for Convenient Preparation of [68Ga]Ga-RM2. Pharmaceutics 2021;13:1160.
29International Atomic Energy Agency. Quality control in the production of radiopharmaceuticals. Iaea Tecdoc 2018;150.
30Pisaneschi F, Viola NT. Development and Validation of a PET/SPECT Radiopharmaceutical in Oncology. Mol Imaging Biol 2022;24:1-7.
